InvestorsHub Logo
Followers 0
Posts 484
Boards Moderated 0
Alias Born 10/10/2014

Re: Oren1976 post# 12

Thursday, 12/28/2017 4:34:32 PM

Thursday, December 28, 2017 4:34:32 PM

Post# of 239
Agree. I think fever is an indication that the immune system has been activate and recruited to fight the cancer. With Toca 511/FC I find it interesting that the company's goal is to create products "designed to activate a patient’s immune system against their own cancer from within."

Also in their earlier studies they found that previously treated mice retained their abilities to fight cancer. This is a sign that the treatment could train the immune system to continue to fight current and future cancerous cells:
"Cellular immunity was evaluated in splenocyte populations
obtained from these previously cured mice by measuring
the number of IFN-? producing cells with ELISPOT
assay. Target cell–stimulated IFN-? responses of splenocytes
derived from cured mice were significantly higher
than splenocytes obtained from naïve control mice (P =
.0005; Fig. 5A). Furthermore, mixed lymphocyte–target
cell reactions using splenocytes from previously cured
animals, monitored by xCELLigence electrical impedance
analysis, showed progressive killing of Tu-2449 target cells
over time in an effector:target ratio–dependent manner,
compared with splenocytes from naïve mice (Fig. 5B, C),
and were similar to those obtained after stimulating splenocytes
from naïve animals with INF-? treated Tu-2449 cells
(Supplementary Fig. S6). Taken together, these results indicate
that RRV-mediated prodrug-activator gene therapy
stimulated endogenous antitumor responses that could be
reactivated >300 days later."
https://tocagen.com/wp-content/uploads/Hiraoka_et_al_Anticancer_Immunity_Neuro-Oncol_2017.pdf